Methods and Compositions for Reducing Serum Levels of Immunoglobulin E (IGE)
AssigneeUniversity of South Florida
InventorsThomas W. Klein, Catherine Newton, Catherine Patterson, Marisela Agudelo
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor CB2 leads to an increase in IgE in serum levels. Conversely, activation of the CB2 receptor by an agonist results in a reduction in IgE serum levels. The compositions and methods of the disclosure, therefore, provide a means to reduce or eliminate symptoms of immune system-related conditions resulting from IgE generation, such as an allergy, hay fever, and the like.
Claims10
A method of reducing the level of immunoglobulin E (IgE) in the serum of an animal or human subject, the method comprising:
- administering to an animal or human subject an effective dose of a pharmaceutical composition comprising an agonist of a CB2 cannabinoid receptor, thereby reducing the level of IgE in the serum of the recipient subject.
A pharmaceutical composition comprising a dose of an agonist of a CB2 cannabinoid receptor and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated to reduce the level of IgE in the serum of the subject animal or human when administered thereto.
Dependencies are inferred from the claim text.